OLIKOS Study: 6-Month Interim Efficacy and Safety in Patients with Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab from Intravenous Anti-CD20 Therapies (P10-6.006)
Neurology（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要